Roth Capital Downgrades Galectin Therapeutics (GALT) to Sell
Tweet
Share
E-mail
Get Alerts GALT Hot Sheet
Price: $3.67 +4.26%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Roth Capital downgraded Galectin Therapeutics (NASDAQ: GALT) from Buy to Sell with a price target of $0.75.
For an analyst ratings summary and ratings history on Galectin Therapeutics click here. For more ratings news on Galectin Therapeutics click here.
Shares of Galectin Therapeutics closed at $2.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Downgrades Diamondback Energy (FANG) to Equalweight
- JPMorgan Downgrades Cogent Communications (CCOI) to Underweight
- CLSA Downgrades Mphasis Ltd. (MPHL:IN) to Underperform (4)
Create E-mail Alert Related Categories
DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
